Four of the 10 drugs subject to Medicare negotiated prices in 2026 theoretically could be displaced by a generic or interchangeable biosimilar on Part D formularies before the end of the year, draft program instructions released by the Centers for Medicare and Medicaid Services suggest.
Medicare Negotiated Drugs Can Face Immediate Generic, Biosimilar Substitution, CMS Proposal Confirms
Stelara, Xarelto, Januvia and Farxiga, which are expected to have biosimilar or generic competition before the end of 2026, could be the first negotiated drugs subject to the policy.
